Asthma control and quality of life improvements vs placebo

The VOYAGE study was a randomised, double-blind, placebo-controlled phase 3 study designed to demonstrate the efficacy and safety of DUPIXENT over a period of up to 52 weeks in children 6–11 years of age with uncontrolled moderate-to-severe* asthma.1

Asthma control and quality of life with DUPIXENT + standard of care (SOC) compared to placebo1

  • Children aged 6–11 years experienced improved✝asthma control when treated with DUPIXENT1,2

     

  • Both patients and their caregivers experienced improvements✝ to their quality of life following the child’s treatment with DUPIXENT2

     

THE DUPIXENT PRE-FILLED SYRINGE


 

Adult and adolescent trial design

Learn more about how the clinical trials have been designed.



Find out more

Safety profile

Learn more about the safety profile of DUPIXENT.



Find out more

Asthma control and Qol

Learn more about how DUPIXENT can help improve asthma control and QoL in adults and adolescents with severe asthma

Find out more

     **Some patients in this study classed as having severe asthma no longer fall into this category, owing to changes in the definition of high-dose ICS.
    †The responder rate was defined as an improvement in score of 0.5 or more

    References

    1. DUPIXENT Summary of Product Characteristics, April 2023.
    2.  Data on file, Sanofi US. LIBERTY ASTHMA VOYAGE. CSR. 2020.
    3.  Juniper EF, et al. Eur Respir J 2010;36(6):1410-1416. doi:10.1183/09031936.00117509.4
    4.  Poachanukoon O, et al. Pediatr Allergy Immunol 2006;17(3):207-212. doi:10.1111/j.1399-3038.2005.00349

MAT-XU-2204215 (v1.0) | Date of preparation: April 2023